Mammalian target of rapamycin (mTOR), a central regulator of protein synthesis in neurons, has been implicated in synaptic plasticity and memory. Here we show that mTOR inhibition by rapamycin in the basolateral amygdala (BLA) or dorsal hippocampus (DH) impairs both formation and reconsolidation of memory for inhibitory avoidance (IA) in rats. Male Wistar rats received bilateral infusions of vehicle or rapamycin into the BLA or DH before or after IA training or retrieval. Memory retention was tested at different time points after drug infusion. Rapamycin impaired long-term IA retention when given before or immediately after training or retrieval into the BLA. When infused into the DH, rapamycin produced memory impairment when given before training or immediately after retrieval. The impairing effects of post-retrieval rapamycin required memory retrieval and were not reversed by a reminder shock. The results provide the first evidence that mTOR in the BLA and DH might play a role in IA memory reconsolidation.
Introduction
Gene expression and protein synthesis are required for longterm memory formation. The protein synthesis-dependent phase whereby newly learned, initially labile, memory traces become stabilized is known as consolidation (McGaugh, 2000) . Consolidation of memory for inhibitory avoidance (IA), a fear conditioning paradigm in which rats or mice learn to avoid a context previously associated with a footshock, is blocked by protein synthesis inhibitors given systemically or infused directly into the dorsal hippocampus (DH) or the basolateral amygdala (BLA) (Flood, Bennett, Orme, & Rosenzweig, 1975; Milekic, Pollonini, & Alberini, 2007; Quevedo et al., 1999; Stäubli, Faraday, & Lynch, 1985) .
The traditional consolidation theory has been challenged by a wave of studies showing that reactivation of a previously consolidated fear-motivated memory during retrieval might render this memory again susceptible to disruption by protein synthesis inhibitors. Thus, a reactivated labile memory would need to undergo a protein synthesis-dependent phase of re-stabilization, a process generally referred to as reconsolidation (Alberini, 2011; Debiec, LeDoux, & Nader, 2002; Nader, Schafe, & Le Doux, 2000; Sara, 2000) , although the exact nature of this phenomenon remains a matter of debate (Alberini, 2005 (Alberini, , 2011 Amaral, Osan, Roesler, & Tort, 2008; Miller & Sweatt, 2006; Nader & Hardt, 2009) . In IA studies, evidence from experiments using systemic or intra-BLA injections of protein synthesis inhibitors have suggested that memory for IA undergoes reconsolidation (Milekic & Alberini, 2002; Milekic et al., 2007) , whereas other studies have found that impairments in IA memory produced by administration of drugs around the time of retrieval are transient and may not be attributed to a deficit of memory storage (Amaral, Luft, Cammarota, Izquierdo, & Roesler, 2007; Power, Berlau, McGaugh, & Steward, 2006) . From a translational point of view, understanding the molecular mechanisms underlying the reconsolidation of fear memories and the effects of pharmacological treatments on reconsolidation has clinical implications for the identification of novel treatment opportunities for fear-related neuropsychiatric disorders including post-traumatic stress disorder (PTSD) (Debiec & LeDoux, 2006; Tronel & Alberini, 2007) .
Mammalian target of rapamycin (mTOR) is a central regulator of protein synthesis in neurons. mTOR is a protein kinase that acts as central component of two multi-protein signaling complexes, mTORC1 and mTORC2. The mTORC1 pathway integrates signaling from neurotransmitter and growth factor receptors to influence the activity of downstream protein kinase pathways, including phosphoinositide 3-kinase (PI3K). mTOR regulates mRNA translation by controlling the phosphorylation state of the eukaryotic initiation factor 4E binding protein (4E-BP1) and p70s6 kinase (p70s6K) (for a review, see Hoeffer & Klann, 2010) . Rapamycin (sirolimus), a naturally occurring macrolide derived from the soil bacterium Streptomyces hygroscopius, potently inhibits mTORC1 activity by associating with the intracellular protein FKBP12, and together they bind the FKBP12-rapamycin-binding (FRB) domain of mTOR, thus preventing mTOR-protein complex formation (for reviews, see Guertin & Sabatini, 2009; Hoeffer & Klann, 2010) .
Recent studies have used rapamycin as a tool to investigate the role of mTOR in memory formation and reconsolidation. Systemic administration of rapamycin impaired the consolidation of memory for contextual fear conditioning (CFC) and reduced subsequent memory retention when given after reactivation (Blundell, Kouser, & Powell, 2008) . Rapamycin given systemically also impaired fearpotentiated startle to a shock-paired context, but did not disrupt startle increases when an odor cue was used (Glover, Ressler, & Davis, 2010) . Consolidation and reconsolidation of CFC were impaired by rapamycin infused directly into the DH (Gafford, Parsons, & Helmstetter, 2011) , and long-term retention of trace fear memory was impaired by rapamycin infused into the medial prefrontal cortex in rats (Sui, Wang, & Li, 2008) . The role of mTOR in memory formation and reconsolidation in the BLA is less understood. One study has indicated that rapamycin given into the amygdala either after training or retrieval reduced memory for cued fear conditioning, however that study did not verify whether memory reactivation was required for the effect of post-retrieval rapamycin and whether the effect was long-lasting or could recover with time .
Only two previous studies examined the role of mTOR in memory for IA, and their findings indicate that IA memory consolidation is dependent on mTOR and sensitive to rapamycin in the DH around the time of training and 3 h after training (Bekinschtein et al., 2007; Slipczuk et al., 2009 ). Previous studies have not examined whether mTOR is involved in IA reconsolidation, or the role of mTOR in the amygdala in memory for IA. Here we used rapamycin infusions to investigate the effects of mTOR inhibition in the BLA or DH, around the time of acquisition or retrieval, on IA memory.
Methods

Animals
Adult male Wistar rats (340-440 g at time of surgery) were obtained from the institutional breeding facility (CREAL, ICBS, UFRGS). Animals were housed five per cage in plastic cages with sawdust bedding, and maintained on a 12 h light/dark cycle at a room temperature of 22 ± 1°C. The rats were allowed ad libitum access to standardized pellet food and water. All experiments took place between 9 AM and 6 PM. All experimental procedures were performed in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the institutional animal care committee under protocol number 09-641.
Surgery
Animals were implanted under anesthesia with ketamine (75 mg/kg) and xylasine (25 mg/kg) with bilateral 14-mm or 9.0-mm, 23-gauge guide cannulae aimed 1.0 mm above the BLA or CA1 area of the DH respectively, as described in previous studies (Quevedo et al., 1999; Roesler et al., 2003) . Coordinates (BLA, anteroposterior, À2.8 mm from bregma, mediolateral, ±4.8 mm from bregma, ventral, À7.5 mm from skull surface; DH anteroposterior, À4.3 mm from bregma; mediolateral, ±3.0 mm from bregma; ventral, À2.0 mm from skull surface) were obtained from the atlas of Paxinos and Watson (2007) . Animals were allowed to recover at least 7 days after surgery.
Drugs and infusion procedures
The general procedures for intra-BLA and intra-DH infusions were as described in previous reports (Amaral et al., 2007; Quevedo et al., 1999; Roesler et al., 2003 Roesler et al., , 2006 . At the time of infusion, a 30-gauge infusion needle was fitted into the guide cannula. The tip of the infusion needle protruded 1.0 mm beyond the guide cannula and was aimed at either the BLA or the CA1 area of the DH. Drug or vehicle (1% dimethylsulfoxide, DMSO, in saline) were infused during a 30-s period. The infusion needle was left in place for an additional minute to allow diffusion of the drug away from the needle tip.
Either 15 min before or immediately after training or the 24-h retention test trial, rats received a bilateral 0.5-ll (BLA) or 1.0-ll (DH) infusion of vehicle or rapamycin (600 nM dissolved in vehicle; Sigma-Aldrich, St. Louis, USA) into either the BLA or DH. The dose of rapamycin was chosen on the basis of previous studies (Bekinschtein et al., 2007; and pilot experiments. Drug solutions were freshly prepared before each experiment.
Inhibitory avoidance (IA)
We used the single-trial step-down IA conditioning as an established model of fear-motivated memory. In step-down IA training, animals learn to associate a location in the training apparatus (a grid floor) with an aversive stimulus (footshock). The general procedures for IA behavioral training and retention test were described in previous reports (Amaral et al., 2007; Quevedo et al., 1999) . The IA apparatus was a 50 Â 25 Â 25-cm acrylic box (Albarsch, Porto Alegre, Brazil) whose floor consisted of parallel caliber stainless steel bars (1 mm diameter) spaced 1 cm apart. A 7-cm wide, 2.5-cm high platform was placed on the floor of the box against the left wall.
On training trials, rats were placed on the platform and their latency to step down on the grid with all four paws was measured with a digital chronometer connected to the box control unit. Immediately after stepping down on the grid, rats received a 0.7-mA, 2.0-s footshock and were removed from the apparatus immediately after the footshock. Retention test trials took place at different time points after training by placing the rats on the platform and recording their latencies to step down. No footshock was presented during retention test trials. In experiments examining possible drug effects on reconsolidation, rats that did not step down to the grid floor within 180 s during the 24-h test trial (''reactivation session'') were gently put on the grid floor for 3 s.
Step-down latencies on the retention test trial (maximum 180 s) were used as a measure of IA memory retention. In some of the experiments, the rats were given a retraining trial 2 weeks after the original training, or a 0.3-mA 2.0-s reminder footshock 1 week after the original training (Tronel & Alberini, 2007) , followed by a retention test 24 h later. Fig. 1 shows a diagram of the design of the experiments used in this study.
Histology
Twenty-four to 72 h after behavioral testing, a 0.5-ll (BLA) or 1.0-ll (DH) infusion of a 4% methylene blue solution was given into the BLA or DH. Rats were killed by decapitation 15 min later, and their brains were removed and stored in 10% formalin for at least 72 h. The brains were sectioned and examined for cannulae placement in the hippocampus and BLA. The extension of the methylene blue dye was taken as indicative of diffusion of the drugs previously given to each rat, as previously described (Amaral et al., 2007; Quevedo et al., 1999; Roesler et al., 2003 Roesler et al., , 2006 . Rats with incorrect cannula placements were excluded from the analysis.
Statistics
Data are mean + SEM retention test latencies to step-down (s). Comparisons of training and retention test step-down latencies between groups were performed using Mann-Whitney U tests, two-tailed (Amaral et al., 2007; Quevedo et al., 1999; Roesler et al., 2003 Roesler et al., , 2006 . In all comparisons, p < 0.05 was considered to indicate statistical significance.
Results
Rapamycin infused into the BLA impairs consolidation of longterm IA memory
We first examined the effects of intra-BLA infusions of rapamycin on memory for IA. Rats were given IA training and tested for retention 3 and 24 h later. Either 15 min before (pretraining infusions) or immediately after (post-training infusions) training, vehicle or rapamycin was infused into the BLA. Rapamycin given 15 min before training significantly decreased IA retention tested at 24 h (p < 0.05), but not at 3 h after training, compared to vehicle-injected controls ( Fig. 2A) . Rapamycin also impaired 24-h retention when infused immediately after training (p < 0.01) (Fig. 2B) . The effects of rapamycin could not be attributed to permanent impairment or neuronal damage, since rats given rapamycin post-training showed normal retention when given a second training drug-free 2 weeks after the original training (Fig. 2C) . Thus, rapamycin infusion in the BLA around the time of acquisition impairs long-, but not short-term memory for IA, indicating that mTOR in the BLA is required for IA memory consolidation.
Rapamycin infused into the BLA before or after retrieval impairs reconsolidation of IA memory
We next examined whether mTOR inhibition in the BLA would affect reconsolidation-like processes by giving rats intra-BLA rapamycin around the time of retrieval. BLA-implanted rats underwent IA training followed by a retention test trial 24 h later. Fifteen minutes before (pre-retrieval infusions), immediately after Inhibition of mTOR by rapamycin in the BLA impairs formation of long-term IA memory. Rats were trained in IA and tested for retention 3 and 24 h later. Vehicle or rapamycin was infused into the BLA either before or after training. (A) Rats were infused with vehicle (N = 9) or rapamycin (N = 9) 15 min before training. When tested for retention 3 h after training both groups had similar latencies. In a second retention test 24 h after training, rats given rapamycin had significantly lower latencies compared to controls ( ⁄ p < 0.05). (B) Rats were infused with vehicle (N = 11) or rapamycin (N = 11) immediately after training. When tested for retention 24 h after training, rats given rapamycin had significantly lower latencies compared to controls ( ⁄⁄ p < 0.01). (C) Rats given post-training rapamycin showed normal IA retention after being giving a retraining drug-free 2 weeks after the original training. There was no significant difference between vehicle and rapamycin-treated rats.
(post-retrieval infusions), or 6 h (delayed infusions) after the 24-retention test, vehicle or rapamycin was infused into the BLA. An additional retention test trial was carried out 48 h after training. There were no significant differences between groups treated with vehicle and rapamycin in training or 24-h test latencies. Intra-BLA rapamycin produced a decrease in IA latency in the 48-h test compared to controls, when given either before (p < 0.01; Fig. 3A ) or immediately after (p < 0.05; Fig. 3B ) training.
We also verified whether the impairing effect of intra-BLA rapamycin given after retrieval would undergo spontaneous recovery or be ameliorated by a reminder (Fig. 3C) . Rats that received intra-BLA infusions after retrieval were again placed on the platform 1 week after the original training and their time to step down was recorded. There was no significant increase in the step down latencies of rapamycin-treated rats in this trial compared to the 48-h test trial. Upon stepping down, rats were given a mild reminder footshock and tested again for retention 24 h later. Latencies in the rapamycin-treated group remained significantly reduced compared to controls (p < 0.05). A separate experiment using a different group of untrained rats confirmed that the reminder shock used (0.3 mA) was sub-threshold, i.e., it did not induce significant 24-h retention by itself (data not shown).
Additional control experiments were performed to confirm the specificity of the effects induced by rapamycin. A ''delayed infusion'' control experiment showed that intra-BLA rapamycin did not affect IA retention when infused 6 h after the 24-h test (Fig. 3D) . Moreover, the impairing effect of rapamycin was dependent on memory retrieval; a ''no reactivation'' control experiment showed that intra-BLA rapamycin given 24 h after training failed to affect 48-h retention in the absence of a retention test trial (Fig. 3E) .
Together, these results suggest that rapamycin infused into the BLA either before or after retrieval impairs IA memory tested in a subsequent retention trial compared to controls. This impairing effect requires memory retrieval associated with the drug infusion, does not recover spontaneously, and is not ameliorated by a Fifteen minutes before the 24-h test, vehicle (N = 11) or rapamycin (N = 12) was infused into the BLA. When re-tested for retention 24 h later (48 h after training), rats given rapamycin had significantly lower latencies compared to vehicle-treated controls ( ⁄⁄ p < 0.01). (B) Rats were trained in IA and tested for retention 24 h later. Vehicle (n = 10) or rapamycin (N = 10) was infused into the BLA immediately after the 24-h test. When re-tested for retention 24 h later (48 h after training), rats given rapamycin showed significantly lower latencies compared to controls ( ⁄ p < 0.05). (C) The impairing effect of post-retrieval rapamycin was not ameliorated by a reminder shock. Rats used in the experiment shown in the previous panel were given a 0.3-mA footshock 1 week after training and tested for retention 24 h later. Latencies in rapamycin-treated rats remained significantly reduced compared to vehicle-treated controls ( ⁄⁄ p < 0.01). (D) Delayed injection control. Rats were trained in IA and tested for retention 24 and 48 h later. Six hours after the 24-h test, vehicle (N = 7) or rapamycin (N = 9) was infused into the BLA. There was no significant difference between groups. (E) No reactivation control. Rats were trained in IA and tested for retention 48 h later. Twenty-four hours after training, vehicle (N = 12) or rapamycin (N = 12) was infused into the BLA in the absence of a retention test. There was no significant difference between groups. reminder shock. Thus, inhibition of mTOR in the BLA might produce deficits in IA memory reconsolidation.
Rapamycin infused into the DH before but not after training impairs long-term IA memory
We then aimed to compare the findings from experiments using intra-BLA infusions of rapamycin with the effects of infusions given into the DH. Rats were trained in IA and tested for retention 3 and 24 h later. Either 15 min before or immediately after training, vehicle or rapamycin was infused into the DH. There was no significant difference between groups in training trial latencies. Rapamycin given 15 min before training significantly decreased IA retention tested at 24 h (p < 0.01), but not at 3 h after training, compared to vehicle-injected controls (Fig. 4A) . However, rapamycin did not affect 24-h retention when infused into the DH immediately after training (Fig. 4B) . Rats given pretraining rapamycin were capable of learning normally when given a second training trial drug-free 2 weeks after the original training (Fig. 4C) . These findings suggest that mTOR inhibition in the DH before acquisition impairs long-, but not short-term memory for IA.
Rapamycin infused into the DH after but not before retrieval impairs reconsolidation of IA memory
In the final set of experiments, we investigated the possible role of hippocampal mTOR in reconsolidation-like processes. Previous studies have indicated that the DH is not involved in IA reconsolidation (Cammarota, Bevilaqua, Medina, & Izquierdo, 2004; Taubenfeld, Milekic, Monti, & Alberini, 2001 ). Rats were trained in IA and given intra-DH infusions of vehicle or rapamycin 15 min before, immediately after, or 6 h after a 24-retention test. An additional retention test trial was carried out 48 h after training. There were no significant differences between groups treated with vehicle and rapamycin in training or 24 h test latencies. Intra-DH rapamycin did not significantly affect 48-h retention when infused before the 24-h test (Fig. 5A) . However, rapamycin given after the 24-h test produced a decrease in IA latency in the subsequent 48-h test compared to controls (p < 0.05; Fig. 5B ).
As with intra-BLA infusions, the rapamycin-induced impairment did not recover spontaneously and was not rescued by a reminder shock (p < 0.01; Fig. 5C ). Moreover, a ''delayed injection'' control experiment showed that intra-DH rapamycin did not affect IA retention when infused 6 h after the 24-h test (Fig. 5D) . Finally, the impairing effect of rapamycin required memory retrieval, as shown by a ''no reactivation'' control experiment (Fig. 5E) . The results indicate that rapamycin infused into the DH after retrieval reduces IA retention tested in a subsequent retention trial, suggesting that mTOR inhibition in the DH impairs reconsolidation.
Histology
Twenty-eight rats implanted in the BLA and 10 rats implanted in the CA1 were excluded from the analysis due to incorrect cannulae placements. Fig. 6 shows representative pictures of cannula locations and a schematic drawing of the spread of dye within the BLA and DH.
Discussion
Together, our results suggest that administration of the mTOR inhibitor rapamycin directly into the BLA or DH can impair both formation and reconsolidation of memory for IA. Only one previous study has examined the effects of rapamycin infused into the BLA on fear memory reconsolidation, however that study did not address whether the impairing effects were reversible and dependent on retrieval . Thus, to our knowledge here we provide the first evidence that intra-BLA rapamycin produces an impairment in fear memory reconsolidation that is not ameliorated by a reminder, and that mTOR in the BLA might be required for IA reconsolidation. Also, our findings provide the first evidence that pharmacological manipulation of the hippocampus after retrieval can produce a deficit in IA memory that does not recover with time or exposure to a reminder. Thus, in contrast to previous studies (Cammarota et al., 2004; Taubenfeld et al., 2001) , the present results suggest that the hippocampus might play a role in reconsolidation of IA memory.
It remains unclear why intra-DH rapamycin impaired formation of IA memory when given before, but not after training, whereas, in contrast, the effects on reconsolidation were produced by infusions given after, but not before retrieval. However, this pattern of effect is similar to that previously observed in experiments using intra-DH infusions of the protein synthesis inhibitor anisomycin (Quevedo Inhibition of mTOR by rapamycin in the DH before but not after training impairs long-term IA memory. Rats were trained in IA and tested for retention 3 and 24 h later. Vehicle or rapamycin was infused into the DH either before or after training. (A) Rats were infused with vehicle (N = 13) or rapamycin (N = 13) 15 min before training. Both groups showed similar latencies in a retention test carried out 3 h after training. In a second retention test 24 h given after training, rats infused with rapamycin showed significantly lower latencies compared to vehicle-treated rats ( ⁄⁄ p < 0.01). (B) Rats were infused with vehicle (N = 8) or rapamycin (N = 7) immediately after training. When tested for retention 24 h after training, both groups showed similar latencies. There was no significant difference between vehicle-and rapamycin-treated rats. (C) Rats given post-training rapamycin showed normal IA retention after a retraining drug-free 2 weeks after the original training. There was no significant difference between vehicle and rapamycintreated rats.
2001). In experiments examining reconsolidation, intra-BLA infusions of rapamycin impaired 48-h retention when given either before or after retrieval, whereas intra-DH infusions had an effect only if given after retrieval. It is possible that this pattern of effects is related to the differential effects of protein synthesis regulated by mTOR on the BLA and DH in fear memory. Previous findings have suggested that fear memory reconsolidation in the BLA requires protein synthesis, but not de novo mRNA synthesis (Parsons, Gafford, Baruch, Riedner, & Helmstetter, 2006; but see Duvarci, Nader, & LeDoux, 2008) . Increasing evidence indicates that mTOR is a key regulator of local protein synthesis induced by synaptic activity (Jiang & Schuman, 2002; Takei et al., 2004) . This local synthesis occurs in specialized zones at dendrites through a mechanism that does not depend on transcription. It is possible that memory reconsolidation in the DH is supported by both global and local protein synthesis, whereas mainly local protein synthesis is required in the BLA, thus resulting in a more salient requirement of mTOR in the BLA.
It is also worth pointing out that rapamycin after training or retrieval reduced, but did not completely block, IA retention, as evidenced by the higher latencies of rapamycin-treated rats in test trials compared to training. However, the effect sizes of rapamycin in our study is comparable to those found in previous studies examining the effects of rapamycin and other protein synthesis inhibitors on reconsolidation of fear memory (Milekic et al., 2007; Taubenfeld et al., 2001) .
In previous studies from our research group, the impairing effects of pharmacological inhibitors given after IA retrieval were transient and recovered spontaneously with time (Amaral et al., 2007; Luft, Amaral, Schwartsmann, & Roesler, 2008) . These transient effects were consistent with those observed in many other studies on post-retrieval treatments and fear memory (for a review, see Amaral et al., 2008) . Thus, we hypothesized that the impairing effects of post-retrieval manipulations could represent, among other possibilities, a ''transient silencing'' of the memory trace undergoing consolidation, rather than a blockade of Fifteen minutes before the 24-h test, vehicle (N = 11) or rapamycin (N = 10) was infused into the DH. When re-tested for retention 24 h later (48 h after training), both groups showed similar latencies. (B) Rats were given IA training and tested for retention 24 h later. Vehicle (N = 7) or rapamycin (N = 7) was infused into the BLA immediately after the 24-h test. When re-tested for retention 24 h later (48 h after training), rats given rapamycin showed significantly lower latencies compared to vehicle-treated controls ( ⁄ p < 0.05). (C) The impairing effect of post-retrieval rapamycin was not ameliorated by a reminder shock. Rats used in the experiment shown in the previous panel were given a 0.3-mA footshock 1 week after training and tested for retention 24 h later. Latencies in the rapamycin-treated group were significantly reduced compared to vehicle-treated rats ( ⁄⁄ p < 0.01). (D) Delayed injection control. Rats were trained in IA and tested for retention 24 and 48 h later. Six hours after the 24-h test, vehicle (N = 8) or rapamycin (N = 8) was infused into the DH. There was no significant difference between groups. (E) No reactivation control. Rats were trained in IA and tested for retention 48 h later. Twentyfour hours after training, vehicle (N = 10) or rapamycin (N = 12) was infused into the DH in the absence of a retention test. There was no significant difference between groups.
''reconsolidation'' (Amaral et al., 2007 . In the present study, in contrast, we observed for the first time a retention impairment induced by post-retrieval manipulation in the IA task that could not be reversed even when animals were given a reminder. Thus, here we interpret our findings adopting the term ''reconsolidation'', as defined operationally by a phenomenon revealed by persistent impairment of memory retention produced by administration of a protein synthesis inhibitor after retrieval. However, the relationship between ''consolidation'' and ''reconsolidation'' remains a matter of debate and will require further understanding of their underlying mechanisms. We have proposed that it may be possible to reconcile apparent discrepant findings from different reconsolidation studies by developing a view of consolidation and reconsolidation as integrated components of the processes mediating long-term memory storage Roesler & McGaugh, 2010) . As proposed originally by Dudai and Eisenberg (2004) , and further developed by Alberini (2005 Alberini ( , 2011 , reconsolidation might be taken as an integral part of a ''lingering consolidation'' process, and a mechanism triggered by retrieval to strengthen the consolidation of recently formed memories.
Our results add to a growing body of evidence, from pharmacological experiments using rapamycin as well as recent genetic studies (Stoica et al., 2011) , indicating that mTOR is a critical molecular regulator of synaptic plasticity and memory. The activity of mTOR is influenced by N-methyl-D-aspartate (NMDA) glutamate receptors and brain-derived neurotrophic factor (BDNF), among other neurotransmitter and neurotrophin pathways. mTOR integrates these signals with downstream signaling pathways such as the PI3K and phosphoinositide dependent kinase-1 (PDK1), to ultimately lead to alterations in mRNA translation and protein synthesis (reviewed in Hoeffer & Klann, 2010) . The role of mTORC1 in regulating consolidation and reconsolidation of fear memory opens a window of opportunity for the development of mTORC1 inhibitors as potential therapeutic agents for the treatment of PTSD and other fear-related psychiatric disorders. Rapamycin is an mTOR inhibitor already in clinical use as an immunosuppressant, and has also been investigated in clinical trials of cancer (Lane & Breuleux, 2009 ). Thus, as previously pointed out by Blundell et al. (2008) , clinical studies of rapamycin combined with reactivation of traumatic memories in patients with PTSD are warranted. Rapamycin analogs such as temsirolimus, as well as secondgeneration mTOR inhibitors that directly target the mTOR catalytic site (Guertin & Sabatini, 2009) , could also be investigated in preclinical studies of fear memory as well as in clinical studies in patients with PTSD.
In conclusion, here we present data consistent with the view that mTOR is importantly involved in fear memory, and provide the first evidence that mTOR in both the amygdala and hippocampus might play a role in reconsolidation of memory for IA. Fig. 6 . Infusion placements into the BLA and DH. Representative brain sections at À2.8 (BLA) and À4.3 mm from bregma showing cannula locations aimed at the BLA and DH, and schematic diagrams of coronal sections of the rat brain, adapted from the atlas of Paxinos and Watson (2007) , depicting the diffusion of methylene blue in the BLA and DH for rats included in the statistical analysis.
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